43 results about "Stress disorders" patented technology

Disclosed herein are compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging, or for modulating one or more energy biomarkers, normalizing one or more energy biomarkers, or enhancing one or more energy biomarkers, wherein the compounds are quinone or naphthoquinone compounds with carboxylic acid or carboxylic acid derivative substituents.

This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for treating stress disorders. Mifepristone, a potent specific glucocorticoid receptor antagonist, can be used in these methods. The invention also provides a kit for treating stress disorders in a human including a glucocorticoid receptor antagonist and instructional material teaching the indications, dosage and schedule of administration of the glucocorticoid receptor antagonist.

The method and apparatus for detecting a chemical substance of the present invention perform the detection of a chemical substance by capturing the chemical substance with a capturing body prepared by utilizing a molecular template. The present invention provides a chemical sensor easy to use for general consumers at home as well as for medical personnel (medical doctors, medical technicians and nurses). In particular, an object of the present invention is to diagnose the symptom of stress disorder by detecting, with high sensitivity, a steroid hormone such as cortisol closely related to stress disorder, and to herewith contribute to the prevention and early treatment of stress disorder. The present invention provides a molecular template for a steroid hormone, including a polymer to interact with the steroid hormone. The polymer preferably includes, in the polymerization unit thereof, two or more functional groups to interact with the steroid hormone.

Substituted pyridines, pyrimidines, pyrazines, pyridinones, pyrimidinones, pyrazinones and phenylacetamides useful in treating depression, stress and other disorders are disclosed. The compounds are of the following formulae.

The subject invention concerns materials and methods for treating and / or preventing diseases associated with accumulation of Aβ peptide in neural tissue. The subject invention also concerns materials and methods for treating and / or preventing stress disorders, such as post-traumatic stress disorder (PTSD). In one embodiment, a method of the invention comprises administering a therapeutically effective amount of cotinine, or a pharmaceutically acceptable salt thereof, to a person or animal in need of treatment. The methods of the invention can be used to prevent and / or treat Alzheimer's disease, Parkinson's disease, and / or Down's syndrome. The subject invention also concerns compositions that comprise cotinine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or adjuvant.The subject invention concerns materials and methods for detecting and diagnosing conditions associated with accumulation of Aβ peptide in neural tissue, such as Alzheimer's disease and Parkinson's disease, using the chemical cotinine. In one embodiment, the method comprises administering cotinine labeled with a detectable label to a person or animal. The presence of labeled cotinine in neural tissue is then determined. The level and / or location of cotinine can be analyzed and a diagnosis made. The subject invention also concerns cotinine labeled with a detectable label. In one embodiment, the cotinine is labeled with a radioisotope that can be detected by Positron Emission Tomography (PET) or single photon emission computed tomography (SPECT).

The present invention comprises novel methods for the use of compositions comprising 7-keto DHEA for treating psychiatric conditions. These methods include administering an effective amount of a composition comprising 7-keto DHEA in an acceptable carrier, alone or in combination with other psychiatric drugs, such as analgesic agents, anticonvulsants, anti-anxiety agents, antidepressants, anti-panic agents, antipsychotic agents, bipolar agents, psychostimulants to reduce or ameliorate symptoms of a psychiatric condition. This method may be used alone or as an adjunctive treatment for treating a wide variety of psychiatric conditions such as stress disorders, anxiety disorders and depressive disorders.

The present invention comprises novel methods for the use of compositions comprising 7-keto DHEA for treating psychiatric conditions. These methods include administering an effective amount of a composition comprising 7-keto DHEA in an acceptable carrier, alone or in combination with other psychiatric drugs, such as analgesic agents, anticonvulsants, anti-anxiety agents, antidepressants, anti-panic agents, antipsychotic agents, bipolar agents, psychostimulants to reduce or ameliorate symptoms of a psychiatric condition. This method may be used alone or as an adjunctive treatment for treating a wide variety of psychiatric conditions such as stress disorders, anxiety disorders and depressive disorders.

The present invention relates to recombinant adeno-associated virus expressing BDNF-HA2TAT, and a construction method thereof. According to the present invention, an adeno-associated virus vector BDNF-HA2TAT / AAV carrying a fusion gene BDNF-HA2TAT is constructed, the recombinant adeno-associated virus expressing BDNF-HA2TAT can secrete and express macromolecule protein BDNF, the expressed BDNF can pass through blood brain barrier, and a BDNF gene sequence is introduced into the AAV vector, such that continuous BDNF secretion expression can be achieved so as to solve the difficult problem of repeated administration required by BDNF; and anti-depression efficacy screening experiment results show that the recombinant adeno-associated virus capable of secreting and expressing BDNF-HA2TAT has an anti-depression effect, and a method for effectively preventing and treating depressive disorders, stress disorders and other mental disorders is established.

Pointing devices such as computer mouse are commonly used for making selections on computer screens. However, prolong or frequent use of such pointing devices might result in users suffering from repetitive stress disorder. Further, due to the widespread use of personal computers (PC), this problem is made more even pronounced. In addition, users increasingly require additional buttons to be provided on the computer mouse for purposes such as PC gaming. Although device manufacturers have started building more buttons on existing computer mice, the buttons are typically not ergonomically positioned. An embodiment of the invention describes an ergonomic input device with multi-programmable buttons.

The invention discloses application of a small dose of propofol in preparing products for preventing and curing post-traumatic stress disorder (PTSD). Stress disorder and its related diseases include acute stress disorder (ASD) and PTSD. According to the test of injecting a small dose of propofol in the abdominal cavity of a PTSD pattern animal, the small dose of propofol has function of relieving fear, anxiety and learning and memory impairment of the PTSD pattern animal, and can decrease expressions of inducible nitric oxide synthase (iNOS) and neurons nitric oxide synthase (nNOS) which are caused by strong stress, increase expression of brain derived neurotrophic factor (BDNF) which plays an important role in neuroplasticity regulation and reduce release of nitric oxide (NO) of glioma cell of the pattern animal greatly. Accordingly, propofol with the advantages of quick action, quick metabolic clearance and no residues has good application prospect.

The present invention provides methods and reagents to quantify endoplasmic reticulum stress (ER stress) levels, and methods and compounds for treating ER stress disorders such as diabetes. Methods for quantifying ER stress in mammalian cells are exemplified.

The subject invention concerns materials and methods for treating depression, stress disorders, such as PTSD, anxiety disorders, and / or a neurodegenerative disease or condition in a person or animal. In one embodiment, a person or animal in need of treatment is administered one or more compounds or drugs, or a composition comprising the one or more compounds or drugs, that inhibit FKBP51 activity or function. The subject invention also concerns a method for inhibiting activity of the FKBP51 protein in a cell. The subject invention also concerns methods of screening for compounds or drugs that inhibit the FKBP51 protein.

The invention discloses application of an adenosine compound WS070133 shown as formula I in preparation of products for prevention or treatment of stress disorders. The stress disorders and related diseases include acute stress disorder, posttraumatic stress disorder, adjustment disorder and phobia, anxiety, mania, bipolar disorder and other diseases. Oral administration of WS070133 on posttraumatic stress disorder model animals shows that the adenosine compound has the effects of lowering animal stress level, reducing fear, anxiety like symptoms and learning and memory impairment. Study also shows that WS070133 can lower the corticosterone level and excitatory amino acid content, reduce apoptosis of neurons and has a regulation effect on related protein molecules. WS070133 has the advantages of low toxicity, no dependence, metabolic and addiction, quick metabolic clearance and no residual effect, etc., thus havaing good application and development prospects. (formula I).

The subject invention concerns materials and methods for treating and / or preventing diseases associated with accumulation of Aβ peptide in neural tissue. The subject invention also concerns materials and methods for treating and / or preventing stress disorders, such as post-traumatic stress disorder (PTSD). In one embodiment, a method of the invention comprises administering a therapeutically effective amount of cotinine, or a pharmaceutically acceptable salt thereof, to a person or animal in need of treatment. The methods of the invention can be used to prevent and / or treat Alzheimer's disease and Parkinson's disease. The subject invention also concerns compositions that comprise cotinine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or adjuvant. The subject invention concerns materials and methods for detecting and diagnosing conditions associated with accumulation of Aβ peptide in neural tissue, such as Alzheimer's disease and Parkinson's disease, using the chemical cotinine.

The invention relates to application of a recombinant adeno-associated virus (AAV) expressing BDNF-HA2TAT in preparing medicaments treating depression diseases. The invention has the advantages that: the recombinant AAV expressing BDNF-HA2TAT of the invention can have secretory expression of the macromolecular protein BDNF (brain derived neurotrophic factor), and the expressed BDNF can pass through a blood-brain barrier, and simultaneously introduction of a BDNF gene sequence into an AAV vector can generate continuous secretory expression of BDNF, thus solving the problem that BDNF needs repeated dosing; anti-depression efficacy screening experiments prove that the recombinant AAV able to have secretory expression of BDNF-HA2TAT has an anti-depression effect, and an approach and method for effective prevention and treatment of mental diseases like depressive disorders and stress disorders can be established.

The invention provides a novel field psychological stress protection system. The system is characterized in that the system comprises a command and control module, a triage rescuing module, a psychological detection module, a psychological stress intervention module and a stress disorder first aid module; the command and control module is respectively connected with the triage rescuing module, thepsychological detection module, the psychological stress intervention module and the stress disorder first aid module to carry out flow management on wounded soldiers, query the information of the wounded soldiers and count the data of the wounded soldiers. The system makes an instant comprehensive injury judgment according to the real-time psychological and physiological state of the rescued personnel to guide classified treatment, and has the advantages of standardized rescuing and curing method, high rescuing and curing efficiency, strong pertinence, and meeting of the rapid, accurate andefficient wartime rescuing and curing requirements. The commander can immediately obtain the individual injury state information of the rescued person and the injury characteristics and types and theflow direction of the wounded soldiers in batches in order to easily make a best command decision.

The present invention generally relates to a method of treating or preventing an endoplasmic reticulum stress disorder in subjects, such as a method of treating or preventing Wolfram syndrome.

The present invention generally relates to a method of treating or preventing an endoplasmic reticulum stress disorder in subjects, such as a method of treating or preventing Wolfram syndrome.

The present invention relates to a pharmaceutical composition for treating or preventing stress disorder, depression, anxiety disorder, comprising 5-benzylaminosalicylic acid derivative or its pharmaceutically acceptable salt. The present invention relates to a method for treating or preventing stress disorder, depression, anxiety disorder, comprising 5-benzylaminosalicylic acid derivative or its pharmaceutically acceptable salt.

The subject invention concerns materials and methods for treating depression, stress disorders, such as PTSD, anxiety disorders, and / or a neurodegenerative disease or condition in a person or animal. In one embodiment, a person or animal in need of treatment is administered one or more compounds or drugs, or a composition comprising the one or more compounds or drugs, that inhibit FKBP51 activity or function. The subject invention also concerns a method for inhibiting activity of the FKBP51 protein in a cell. The subject invention also concerns methods of screening for compounds or drugs that inhibit the FKBP51 protein.

The present invention is concerned with deuterium-enriched pyrimidine compounds of formula 1, their derivatives and pharmaceutically acceptable salts and methods of use thereoffor the prevention and treatment of neuroendocrine neoplasia including metastasis and fibrosis, fibrotic processes associated with neuroendocrine cell dysregulation for example Crohn's disease, pulmonary arterial hypertension, pulmonary hypertension associated with chronic obstructive pulmonary disease (COPD), right ventricular hypertrophy, pulmonary vascular remodeling, asthma, cystic fibrosis, hypertension, ischemic stroke, angina pectoris, congestive heart failure, arrhythmia, arterial fibrillation, neurodenerative diseases, gastrointestinal disorders , stress disorders, obsessive compulsive disorders, demyelinating diseases, cereberal vascular disorders, bronchoconstriction, vasodilation, smooth muscle contraction, brain disorders, vascular disorders, neuropathological diseases and cardiovascular system regulation.

The invention belongs to the technical field of traditional Chinese medicines, and in particular relates to a traditional Chinese medicinal composition for preventing or treating military stress disorders and a preparation method of the traditional Chinese medicinal composition. The traditional Chinese medicinal composition is prepared from lucid ganoderma, lucid ganoderma spore, herba dendrobii, radix ginseng, radix astragali, glossy privet fruits, fructus schisandrae, fermented soybean and dried tangerine or orange peel at a certain ratio. The traditional Chinese medicinal composition has the efficacies of benefiting qi for promoting production of fluid, tonifying the kidney and the spleen, tranquilizing the mind by nourishing the heart, relieving the exterior syndromes and restlessness, dispersing stagnated liver qi to relieve depression, nourishing Yin and suppressing Yang, and improving the body immunity. The pharmacological test proves that the traditional Chinese medicinal composition can obviously improve the behavior abnormality and immunologic function biochemical index change of stress disorder model rats, and has the efficacy of treating both manifestation and root cause of diseases. The clinical verification result shows that the traditional Chinese medicinal composition has the effective prevention and treatment effects for the stress disorders caused by various stimulating factors, and can obviously improve the symptoms including dysphoria and aypnia, willies, melancholy, moodiness, headache and heavy feeling in the brain, loss of appetite, fatigue and indolence, immunity decline, and the like.

A system for generating a stress disorder ration program includes a computing device configured to obtain a stress representation, ascertain an equanimity signature, wherein ascertaining the equanimity signature further comprises retrieving an acclimation element, determining a relative vector as a function of the acclimation element, and ascertaining the equanimity signature as a function of the relative vector and the stress representation using a stress machine-learning model, identify a physiological influence as a function of the equanimity signature, determine an edible as a function of the physiological influence, and generate a ration program as a function of the edible.

The invention is composition and methods that restore balance to the stress-related steroidal hormone cascade. Upon co-administration, the compounds of the invention restore balance to the cascade and promote or restore normal function in patients suffering from a disorder having a primary psychological stress component. The compositions include a selected combination of isoflavones, alpha lipoic acid, and L dopamine or a precursor thereof, and are preferably obtained from the natural sources disclosed herein. The uses of the invention include administration of the disclosed compositions to patients suffering from PTSD, fibromyalgia, endometriosis, and other disorders having a common chronic stress component.

The present invention generally relates to a method of treating or preventing an endoplasmic reticulum stress disorder in subjects, such as a method of treating or preventing Wolfram syndrome.

The present invention is concerned with deuterium-enriched pyrimidine compounds of formula I, their derivatives and pharmaceutically acceptable salts and methods of use thereof,The compounds of formula I are useful for the prevention and treatment of liver fibrosis and cirrhosis, hepatocellular carcinoma, neuroendrcrine neoplasia including metastasis and fibrosis fibrotic processes associated with neuroendocrine cell dysregulation for example Crohn's disease, pulmonary arterial hypertension, pulmonary hypertension associated with chronic obstructive pulmonary disease (COPD), right ventricular hypertrophy, pulmonary vascular remodeling, asthma, cystic fibrosis, hypertension, ischemic stroke, angina pectoris, congestive heart failure, arrhythmia, arterial fibrillation, gastrointestinal disorders, anxiety, depression, stress disorders, post-traumatic stress disorder, obsessive compulsive disorders, demyelinating diseases, acute or chronic cerebrovascular damage, cerebral infarction, subarachanoid hemorrhage, and cerebral edema, neuropathological diseases and cardiovascular system regulation.

The subject invention concerns materials and methods for treating depression, stress disorders, such as PTSD, anxiety disorders, and / or a neurodegenerative disease or condition in a person or animal. In one embodiment, a person or animal in need of treatment is administered one or more compounds or drugs, or a composition comprising the one or more compounds or drugs, that inhibit FKBP51 activity or function. The subject invention also concerns a method for inhibiting activity of the FKBP51 protein in a cell. The subject invention also concerns methods of screening for compounds or drugs that inhibit the FKBP51 protein.